Search details
1.
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
Eur Radiol
; 33(2): 1174-1184, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-35976398
2.
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Int J Cancer
; 150(1): 112-123, 2022 01 01.
Article
in English
| MEDLINE | ID: mdl-34431518
3.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Br J Cancer
; 127(5): 836-843, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35637412
4.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Br J Cancer
; 124(3): 587-594, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33154570
5.
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
Int J Cancer
; 142(5): 1047-1055, 2018 03 01.
Article
in English
| MEDLINE | ID: mdl-29047142
6.
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
Int J Cancer
; 140(8): 1918-1925, 2017 Apr 15.
Article
in English
| MEDLINE | ID: mdl-28032641
7.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Lancet Oncol
; 17(10): 1426-1434, 2016 Oct.
Article
in English
| MEDLINE | ID: mdl-27575024
8.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(10): 1065-75, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-25088940
9.
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.
Eur J Cancer
; 137: 250-259, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32810748
10.
Specific targeting of hepatitis C virus core protein by an intracellular single-chain antibody of human origin.
Hepatology
; 48(3): 702-12, 2008 Sep.
Article
in English
| MEDLINE | ID: mdl-18697213
11.
Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250-259].
Eur J Cancer
; 169: 223-225, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35570084
12.
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306).
Oncotarget
; 8(62): 105749-105760, 2017 Dec 01.
Article
in English
| MEDLINE | ID: mdl-29285289
13.
[Update hepatitis D]. / Update Hepatitis D.
Med Klin (Munich)
; 101 Suppl 1: 127-34, 2006 Mar 22.
Article
in German
| MEDLINE | ID: mdl-16802537
14.
SEN virus has an adverse effect on the survival of HIV-positive patients.
AIDS
; 19(10): 1091-6, 2005 Jul 01.
Article
in English
| MEDLINE | ID: mdl-15958841
15.
SEN virus seroprevalence in HIV positive patients: association with immunosuppression and HIV-replication.
J Clin Virol
; 33(3): 183-7, 2005 Jul.
Article
in English
| MEDLINE | ID: mdl-15911438
16.
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
J Clin Oncol
; 33(32): 3718-26, 2015 Nov 10.
Article
in English
| MEDLINE | ID: mdl-26261259
17.
Cloning and molecular characterization of human high affinity antibody fragments against Hepatitis C virus NS3 helicase.
J Virol Methods
; 103(1): 75-88, 2002 May.
Article
in English
| MEDLINE | ID: mdl-11906735
18.
SEN virus does not affect treatment response in hepatitis C virus coinfected patients but SEN virus response depends on SEN virus DNA concentration.
World J Gastroenterol
; 10(13): 1893-7, 2004 Jul 01.
Article
in English
| MEDLINE | ID: mdl-15222031
19.
Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
Liver Int
; 27(7): 954-9, 2007 Sep.
Article
in English
| MEDLINE | ID: mdl-17696934
20.
Treatment of chronic hepatitis delta with pegylated interferon-alpha2b.
Liver Int
; 26(7): 805-10, 2006 Sep.
Article
in English
| MEDLINE | ID: mdl-16911462